Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04145011
Other study ID # 105-18-0002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 4, 2019
Est. completion date October 10, 2022

Study information

Verified date August 2023
Source Avanos Medical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is being performed to assess the relative effectiveness of genicular nerve ablation with the COOLIEF* Cooled Radiofrequency probe to manage moderate to severe knee pain in patients with osteoarthritis (OA) of the knee when compared to radiofrequency ablation using a Standard Radiofrequency probe.


Description:

This is a prospective, multi-center, randomized, single-blind comparison study examining the outcomes of subjects with osteoarthritic knee pain undergoing a procedure to create a radiofrequency lesion of the genicular nerves with either Cooled Radiofrequency Ablation (CRFA) or Conventional (Standard) Radiofrequency Ablation (SRFA). Approximately 148 participants from up to 15 sites will be enrolled into this study, with subjects undergoing either CRFA or SRFA in a 1:1 randomization scheme. Follow-up will be conducted for 24 months post-treatment, with the primary endpoint being completed at month 12. Pain, overall outcome, quality of life, pain medication use, and adverse events will be compared between the two treatment groups to determine success.


Recruitment information / eligibility

Status Completed
Enrollment 153
Est. completion date October 10, 2022
Est. primary completion date October 29, 2021
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: 1. Age = 21 years 2. Able to understand and personally sign and date the informed consent form 3. Able to complete outcome measures 4. Chronic knee pain for longer than 6 months that interferes with functional activities (for example, ambulation, prolonged standing, etc.) 5. Continued pain in the target knee despite at least 3 months of conservative treatments, including activity modification, home exercise, protective weight bearing, and/or analgesics (for example, acetaminophen or non-steroidal anti-inflammatory drugs [NSAIDs]) 6. Positive response (defined as a decrease in numeric pain scores of at least 50%) to a single genicular nerve block of the index knee 7. Pain on NRS = 6 on an 11-point scale for the index knee 8. Radiologic confirmation of osteoarthritis (x-ray/MRI/CT) grade 2 (mild), 3 (moderate) or 4 (severe) noted within 6 months for the index knee 9. Analgesics including membrane stabilizers such as Neurontin (gabapentin) and antidepressants for pain, such as Cymbalta (duloxetine), must be clinically stable (defined as stable dosage for = 6 weeks prior to the screening visit) and shall not change during the course of the study without approval of the investigator 10. Agree to see one physician (study physician) for knee pain during the study period 11. Subjects of child bearing potential must be willing to utilize double barrier contraceptive method 12. Willingness to comply with the requirements of this protocol for the full duration of the study (24 months regardless of effect of initial therapy) Exclusion Criteria: 1. Evidence of inflammatory arthritis (example, rheumatoid arthritis) or other systemic inflammatory condition (example; gout, fibromyalgia, MS, Lupus, etc.) that could cause knee pain 2. Evidence of neuropathic pain affecting the index knee 3. Previous or pending lower limb amputation 4. Intra-articular steroid injection into the index knee within 90 days from randomization 5. Hyaluronic acid injection, platelet rich plasma (PRP), stem cell, or arthroscopic debridement/lavage injection into the index knee within 180 days from randomization 6. Prior radiofrequency ablation of the genicular nerves of the index knee 7. Prior partial, resurfacing, or total knee arthroplasty of the index knee (residual hardware) 8. Clinically significant ligamentous laxity of the index knee 9. Clinically significant valgus/varus deformities or evidence of pathology (other than osteoarthritis of knee) that materially affects gait or function of the knee or is the underlying cause of the knee pain and/or functional limitations 10. Body mass index (BMI) > 40 kg/m2 11. Extremely thin patients and those with minimal subcutaneous tissue thickness that would not accommodate a radiofrequency lesion of up to 14 mm in diameter to limit the risk of skin burns 12. Pending or active compensation claim, litigation, or disability remuneration (secondary gain) 13. Pregnant, nursing or intent of becoming pregnant during the study period 14. Chronic pain associated with significant psychosocial dysfunction 15. Poorly controlled severe psychiatric illness or ongoing psychological barriers to recovery, as determined by the investigator 16. Allergies to any of the medications to be used during the procedures 17. Active joint infection or systemic or localized infection at needle entry sites (subject may be considered for inclusion once infection is resolved) 18. History of uncontrolled coagulopathy, ongoing coagulation treatment that cannot be safely interrupted for procedure, or unexplained or uncontrollable bleeding that is uncorrectable 19. Identifiable anatomical variability that would materially alter the procedure as described in the protocol 20. Within the preceding 2 years, subject has suffered from active narcotic addiction, substance, or alcohol abuse 21. Current prescribed opioid medications greater than 60 mg morphine equivalent daily opioid dose 22. Uncontrolled immunosuppression (e.g. AIDS, cancer, diabetes, etc.) 23. Subject currently implanted with pacemaker, stimulator or defibrillator 24. Participating in another clinical trial/investigation which included therapeutic treatment within 30 days prior to signing informed consent 25. Subject unwilling or unable to comply with follow up schedule, protocol requirements or procedures

Study Design


Intervention

Device:
Cooled Radiofrequency
Delivery of energy to ablate sensory nerves via cooled radiofrequency probe (18g, 4mm active tip)
Standard Radiofrequency
Delivery of energy to ablate sensory nerves via non-cooled standard radiofrequency probe (22g, curved 10mm active tip)

Locations

Country Name City State
United States University Orthopedics Center Altoona Pennsylvania
United States Piedmont Comprehensive Pain Management Anderson South Carolina
United States The Spine and Nerve Centers of St. Francis Hosptial Charleston West Virginia
United States University of Virginia Charlottesville Virginia
United States University of Utah Salt Lake City Utah
United States Pain Diagnostics and Interventional Care Sewickley Pennsylvania
United States University Orthopedics Center State College Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Avanos Medical

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Numeric Rating Scale (NRS) The proportion of subjects whose knee pain is reduced by = 50% based on the NRS. The NRS is an 11-point scale (0 points to 10 points), where 0 points equals "no pain" and 10 points equals "worst pain". There are no sub-scales. 24 months
Other Additional Interventions The proportion of subjects requiring additional intervention for their OA knee pain. 24 months
Other Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS, JR) The change in KOOS JR score from baseline. The KOOS JR is a short form of the KOOS that assesses patient stiffness (1 item), pain (4 items), and functions of daily living (2 items). Scores range from 0 to 100 with a score of 0 indicating total knee disability and 100 indicating perfect knee health. 24 months
Other EQ-5D-5L The change in measured EQ-5D-5L scale from baseline. This outcome instrument is composed of five sub-scales containing five questions each. The point range for each sub-scale is from 1 to 5, with "1" indicating the best study subject condition and "5" indicating the worst study subject condition. Thus, the minimum and maximum scores per sub-scale are 1 and 5, respectively, and such scores for the entire instrument are 5 (best study subject condition) and 25 (worst study subject condition). The sub-scale topics are: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression 24 months
Other Global Perceived Effect (GPE) The measured Global Perceived Effect scale. The Global Perceived Effect is a 7-point scale: 1 point = "worst ever", 2 points = "much worse", 3 points = "worse", 4 points = "not improved but not worse", 5 points = "improved", 6 points = "much improved", 7 points = "best ever". There are no sub-scales. 24 months
Primary Numeric Rating Scale (NRS) The proportion of subjects whose knee pain is reduced by = 50% based on the NRS. The NRS is an 11-point scale (0 points to 10 points), where 0 points equals "no pain" and 10 points equals "worst pain". There are no sub-scales. 12 months
Secondary Additional Interventions The proportion of subjects requiring additional intervention for their OA knee pain. 12 months
Secondary Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS, JR) The change in KOOS JR score from baseline. The KOOS JR is a short form of the KOOS that assesses patient stiffness (1 item), pain (4 items), and functions of daily living (2 items). Scores range from 0 to 100 with a score of 0 indicating total knee disability and 100 indicating perfect knee health. 12 months
Secondary EQ-5D-5L The change in measured EQ-5D-5L scale from baseline. This outcome instrument is composed of five sub-scales containing five questions each. The point range for each sub-scale is from 1 to 5, with "1" indicating the best study subject condition and "5" indicating the worst study subject condition. Thus, the minimum and maximum scores per sub-scale are 1 and 5, respectively, and such scores for the entire instrument are 5 (best study subject condition) and 25 (worst study subject condition). The sub-scale topics are: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression 12 months
Secondary Global Perceived Effect (GPE) The measured Global Perceived Effect scale. The Global Perceived Effect is a 7-point scale: 1 point = "worst ever", 2 points = "much worse", 3 points = "worse", 4 points = "not improved but not worse", 5 points = "improved", 6 points = "much improved", 7 points = "best ever". There are no sub-scales. 12 months
See also
  Status Clinical Trial Phase
Completed NCT03277066 - A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis Phase 2
Recruiting NCT03090698 - Outcomes of Injections in Patients Waiting for Total Knee Replacement Phase 4
Completed NCT02556710 - A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee Phase 3
Completed NCT02242435 - A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis Phase 3
Withdrawn NCT02237846 - Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis Phase 1/Phase 2
Completed NCT02096393 - Patient Specific Instrumentation in TKR N/A
Completed NCT01849445 - Targeted Rehabilitation to Improve Outcome After Knee Replacement- A Physiotherapy Study N/A
Completed NCT01704157 - A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device N/A
Active, not recruiting NCT01374230 - Long-Term Multicenter Evaluation of the E1® Tibial Bearing N/A
Completed NCT02156440 - Cross-over Study of the Efficacy and Safety of SierraSil Joint Formula 14 in Osteoarthritis of the Knee Phase 2
Completed NCT01410409 - Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement N/A
Not yet recruiting NCT01270412 - Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis PRP as a Treatment for Knee Osteoarthritis Phase 2/Phase 3
Completed NCT01207115 - A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee Phase 2
Completed NCT00970008 - Exploring Massage Benefits for Arthritis of the Knee Phase 2
Completed NCT00988091 - Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee Phase 3
Completed NCT01331278 - A Comparative Study of Knee Systems Phase 4
Completed NCT00792727 - HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain Phase 3
Completed NCT00531427 - Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee Phase 3
Completed NCT00449696 - Gel-200 Versus Placebo in Osteoarthritis of the Knee Phase 3
Completed NCT01430559 - Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee N/A